Patent Law Weblog
recent posts
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
- Meanwhile, Back at the PTAB with CRISPR – Update
about
Category: Food and Drug Administration
-
By Kevin E. Noonan — The Food and Drug Administration posted a notice on its website today that further restricts prescription of two erythropoietin drugs (Amgen’s Epogen®/Aransesp® and Johnson & Johnson’s Procrit®) to cancer patients. The notice is part of the FDA’s ongoing safety review of these drugs, and is a "follow-up" to…
-
By Kevin E. Noonan — One of the promises of the genomics revolution of the late 20th Century is the advent of personalized medicine. The belief was (and is) that the unfolding understanding of genetic variation stemming from sequence analysis of genes known or discovered to be involved in an individual’s response to…
-
By Kevin E. Noonan — On Friday, the Court of Appeals for the Federal Circuit handed Pfizer a mixed decision on defendant Teva’s appeal of a District Court judgment that Teva was liable for infringing a trio of Pfizer patents (U.S. Patent Nos. 5,466,823; 5,563,165; and 5,760,068) relating to the pain medication Celebrex®…
Patent Docs 